{
    "Trade/Device Name(s)": [
        "Elecsys CMV IgM Immunoassay",
        "Elecsys PreciControl CMV IgM"
    ],
    "Submitter Information": "Roche Diagnostics Corporation",
    "510(k) Number": "K142133",
    "Predicate Device Reference 510(k) Number(s)": [
        "K001767",
        "K092322"
    ],
    "Regulatory Class": "Class II, Class I",
    "Product Code(s)": [
        "LFZ",
        "JJX"
    ],
    "Summary Letter Date": "August 1, 2014",
    "Summary Letter Received Date": "August 4, 2014",
    "Submission Date": "October 23, 2014",
    "Regulation Number(s)": [
        "21 CFR 866.3175",
        "21 CFR 862.1660"
    ],
    "Regulation Name(s)": [
        "Cytomegalovirus serological reagents",
        "Single (Specified) Analyte Controls (Assayed and Unassayed)"
    ],
    "Analyte Class(es)": [
        "virology",
        "immunology"
    ],
    "Analyte(s)": [
        "Cytomegalovirus IgM antibody"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Lithium-heparin plasma",
        "K2-EDTA plasma",
        "K3-EDTA plasma"
    ],
    "Specimen Container(s)": [
        "Serum separator tube",
        "Lithium-heparin tube",
        "K2-EDTA tube",
        "K3-EDTA tube"
    ],
    "Instrument(s)/Platform(s)": [
        "Elecsys 2010 analyzer",
        "MODULAR ANALYTICS E170 analyzer",
        "cobas e immunoassay analyzers"
    ],
    "Method(s)/Technology(ies)": [
        "Electrochemiluminescence immunoassay (ECLIA)",
        "\u03bc-capture immunoassay"
    ],
    "Methodologies": [
        "Immunoassay",
        "Electrochemiluminescence detection",
        "\u03bc-capture format"
    ],
    "Submission Type(s)": [
        "Assay",
        "Quality control material",
        "Calibrator",
        "Reagent",
        "Analyzer"
    ],
    "Document Summary": "FDA 510(k) summary for Elecsys CMV IgM Immunoassay and Elecsys PreciControl CMV IgM for qualitative detection and quality control of CMV IgM antibodies in serum and plasma using electrochemiluminescence on Elecsys platforms",
    "Indications for Use Summary": "In vitro qualitative detection of IgM antibodies to cytomegalovirus in serum, lithium-heparin plasma, K2-EDTA and K3-EDTA plasma to aid diagnosis of recent or current CMV infection in individuals, including pregnant women; not intended for neonatal screening, point-of-care, or blood/plasma donor screening.",
    "fda_folder": "Microbiology"
}